Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  etoposide phosphate
Find trials that include:  Any drugs shown
Results 1-25 of 35 for your search:
Start Over
Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under at the time of definitive surgery
Trial IDs: ACNS0333, NCI-2009-00337, CDR0000592812, COG-ACNS0333, NCT00653068
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors
Phase: Phase III
Type: Treatment
Age: 14 and over
Trial IDs: A031102, NCI-2014-01696, PA031102_A01PAMDREVW01, NCT02375204
Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 to 75
Trial IDs: SOL-04058-L, NCI-2013-00786, 2868, OHSU-8507, OHSU-2868, OHSU-SOL-04058-L, NCT00303849
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Phase: Phase II, Phase I
Type: Treatment
Age: 1 to 21
Trial IDs: T2008-002, NCI-2011-02779, NCT00981799
MLN4924, Combination Chemotherapy, and Rituximab in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-C-0216, NCI-2013-01498, 110216, P10797, NCT01415765
Yttrium Y 90 Daclizumab and Combination Chemotherapy before Stem Cell Transplant in Treating Patients with Recurrent or Refractory Hodgkin’s Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 12-C-0003, NCI-2013-01512, 120003, P11859, NCT01468311
Radiolabeled Monoclonal Antibody and Combination Chemotherapy before Stem Cell Transplant in Treating Patients with High-Risk Lymphoid Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2728.00, NCI-2013-01378, NCT01921387
Combination Chemotherapy With or Without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients With Malignant Brain Tumors
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 to 75
Trial IDs: ONC-02019-L, NCI-2013-00781, eIRB #922, OHSU-7328, OHSU-922, OHSU-ONC-02059-L, CASE-CCF-6385, NCT00075387
Alemtuzumab, Combination Chemotherapy, and Rituximab in Treating Patients with Relapsed or Refractory Diffuse Large B-Cell or Hodgkin Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10-C-0011, NCI-2013-01454, 100011, P09557, NCT01030900
Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients with Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GOG-0264, NCI-2011-02000, CDR0000662814, NCT01042522
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CD-ON-MEDI-551-1088, NCI-2012-00735, NCT01453205
Combination Chemotherapy before Peripheral Blood Stem Cell Transplant in Treating Patients with Hodgkin or Non-Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 to 75
Trial IDs: 201312115, NCI-2013-02212, NCT01969435
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients with Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: ANHL12P1, NCI-2013-02167, COG-ANHL12P1, NCT01979536
Combination Chemotherapy and Radiation Therapy in Treating Patients with Newly Diagnosed Stage I-II Nasal NK Cell Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2013-0367, NCI-2014-01356, NCT02106988
Microtransplantation in Treating Younger Patients with Refractory or Relapsed Hematological Malignancies
Phase: Phase II
Type: Treatment
Age: 21 and under
Trial IDs: MITREL, NCI-2015-00691, NCT02433483
Vorinostat, Niacinamide, and Etoposide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: NYU 09-0621, NCI-2011-02695, NCT00691210
Belinostat, Cisplatin, and Etoposide in Treating Patients with Recurrent or Advanced Small Cell Lung Cancer or Neuroendocrine Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 09-C-0173, NCI-2013-01451, 090173, 09-25-0099, NCI 8238, P09511, P8238_A22PAMDREVW01, 8238, NCT00926640
Radiation Therapy, Cisplatin, and Etoposide in Treating Patients with Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
Phase: Phase I
Type: Treatment
Age: not specified
Trial IDs: 7506, NCI-2011-01752, NCT01411098
Hypofractionated Proton Beam Radiation Therapy, Cisplatin, and Etoposide Followed by Surgery in Treating Patients with Stage IIIA-B Non-small Cell Lung Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-253, NCI-2012-00672, NCT01565772
Erismodegib, Etoposide, and Cisplatin as First-Line Therapy in Treating Patients with Extensive Stage Small Cell Lung Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-206, NCI-2012-00568, NCT01579929
Phase I Study of Romidepsin Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2012-0183, NCI-2012-00847, NCT01590732
A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: HGS1036-C1118, NCI-2012-01245, NCT01604863
Brentuximab Vedotin, Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-040, NCI-2013-01114, NCT01830777
Start Over